WHY IT MATTERS: If you are a parent, caregiver, or young adult patient, this research reinforces that cannabis therapies should be reserved for adults with clinical oversight, and that adolescent use without medical necessity carries real psychiatric risk. CLINICAL OVERVIEW: Large-scale research continues to reinforce what clinicians have observed for years: adolescent cannabis use is associated with increased risk of psychotic disorders, depression, and anxiety later in life. The developing brain, particularly before age 25, is uniquely vulnerable to the effects of THC on endocannabinoid system signaling, and early exposure may alter neurodevelopmental trajectories in ways that increase psychiatric risk.
Teens Who Use Cannabis Face Higher Risk Of Mental Disorders, Study Finds – Forbes
WHY IT MATTERS: If you are a parent or caregiver of a teenager, this research reinforces why cannabis medicine should only be considered for adolescents under direct physician supervision with clear medical necessity, and why recreational teen use carries real psychiatric risk. CLINICAL OVERVIEW: Adolescent cannabis use has consistently been associated with increased risk of psychiatric disorders in the clinical literature, and new large-scale data continues to reinforce this concern. The developing brain is particularly vulnerable to exogenous cannabinoids, and early exposure during critical neurodevelopmental windows may alter endocannabinoid signaling in ways that predispose teens to conditions like psychosis, anxiety disorders, and depression.
A huge study finds a link between cannabis use in teens and psychosis later – NPR
WHY IT MATTERS: If you are a parent, caregiver, or young adult considering cannabis, this research underscores why medical guidance, age-appropriate restrictions, and honest conversations about brain development should be part of any decision about use. CLINICAL OVERVIEW: Large-scale longitudinal research continues to reinforce what clinicians in cannabis medicine have long recognized: the adolescent brain is uniquely vulnerable to cannabinoid exposure, and early use is associated with elevated risk of psychotic disorders in adulthood. This does not mean cannabis inevitably causes psychosis, but it does mean that age of onset, frequency of use, and genetic predisposition are critical variables that deserve serious clinical attention.
Do anything, become nothing – The Morning News
WHY IT MATTERS: If you are a parent, caregiver, or young adult considering cannabis, this study reinforces that adolescent brain development is a critical window where unsupervised use may carry serious long-term psychiatric risks that do not necessarily apply to adult medical patients under clinical guidance. CLINICAL OVERVIEW: A new longitudinal study links adolescent cannabis use to increased risk of later bipolar and psychotic disorder diagnoses, adding to a growing body of evidence that the developing brain is uniquely vulnerable to cannabinoid exposure. While this research does not apply directly to adult medical cannabis patients, it reinforces what clinicians in cannabis medicine have long emphasized: age of onset matters enormously, and adolescent use carries a fundamentally different risk profile than supervised adult medical use.
Teens Using Weed Have Doubled Risk For Psychosis, Bipolar Disorder
New research is sounding the alarm on teen cannabis use and mental health risk. Here’s what you need to know: Study tracked teens through age 26 Results showed doubled risk for psychosis and bipolar disorder in teen users ️ The developing brain is uniquely vulnerable to THC exposure ️ This is why cannabis medicine physicians distinguish between adult therapeutic use and adolescent recreational use ️ Age-appropriate care matters As a physician who has treated over 30,000 patients, I firmly believe cannabis has real medical value for adults. But that belief comes with a responsibility to be honest: the teen brain is still under construction, and we need to protect it. Talk to your kids. Talk to your doctor. Get the facts. New research links teen cannabis use to doubled psychosis and bipolar risk by age 26. The developing brain deserves different rules than the adult brain.
Cannabis Use Associated with Worse Working Memory – EMJ
New research links heavy cannabis use to reduced brain activation during memory tasks. Here’s what you need to know: The study focused on heavy use patterns, not structured medical dosing Dose, frequency, and cannabinoid profile all matter for cognitive outcomes Working memory changes may be more pronounced with high-THC, high-frequency use ️ Medical patients using low-to-moderate doses under guidance face a different risk profile This is why we monitor cognitive function and adjust protocols over time The takeaway? Cannabis isn’t one-size-fits-all, and neither is the research. Talk to your cannabis clinician about what this means for YOUR care. Heavy cannabis use may impair working memory, but dose and context matter enormously. Medical patients deserve nuance, not headlines.
Study: Teen Cannabis Use Linked to Double Psychosis Risk – Ground News
New research links adolescent cannabis use to a significantly higher risk of psychosis. Here’s what you need to know: Teen cannabis use was associated with roughly 2x the risk of developing psychotic disorders Genetic predisposition and frequency of use likely play major roles ️ The adolescent brain is still developing well into the mid-20s Medical cannabis programs screen for psychiatric risk factors for exactly this reason This is not about fear — it’s about informed, age-appropriate decisions Cannabis can be powerful medicine for adults under proper guidance. But for teens, the risk-benefit equation is very different. Talk to your kids. Talk to your doctor. Knowledge is harm reduction. New study links teen cannabis use to doubled psychosis risk. This is why age, dose, and clinical oversight matter.
Kaiser Study Finds Higher Risk of Psychiatric Disorders in Teens Who Reported Cannabis Use
New research from Kaiser Permanente highlights psychiatric risks tied to teen cannabis use. Here’s what clinicians and families need to know: The adolescent brain is still developing its endocannabinoid system, making it more vulnerable to disruption ️ Association does not equal causation, but the signal is strong enough to warrant caution ️ Adult medical cannabis under supervision is a very different scenario than unsupervised teen use Age-appropriate protocols, dosing, and monitoring are critical for any adolescent cannabis consideration Open conversations between parents, teens, and clinicians are the best harm reduction tool we have Cannabis is powerful medicine. That’s exactly why it deserves respect, especially when young brains are involved. New Kaiser study links teen cannabis use to higher psychiatric risk. The adolescent brain is not the adult brain, and our approach to cannabinoid medicine must reflect that.
Study: Teen Cannabis Use Linked to Double Psychosis Risk
This is one of the largest studies ever conducted on teen cannabis use and psychiatric outcomes, and it reinforces that age restrictions and youth prevention should be central to any legalization framework. A JAMA Health Forum study of 463,396 adolescents ages 13 to 17 found cannabis use was linked to a twofold increase in psychotic and bipolar disorder risk by age 26. The study represents one of the largest longitudinal investigations of this association, drawing on clinical health records rather than self-reported data.
Cannabis Use by Teenagers Doubles Their Risk of Developing Psychotic and Bipolar Disorders
With cannabis potency at historic highs, this study underscores that adolescent brains are uniquely vulnerable to THC exposure, and parents should understand the psychiatric risks before dismissing cannabis as harmless. Data from a JAMA Health Forum study of nearly half a million teenagers demonstrates that adolescent cannabis use doubles the risk of psychotic and bipolar disorder diagnoses by early adulthood. The association persisted across demographic subgroups and was temporally consistent, with cannabis use preceding psychiatric diagnoses by roughly two years on average.